Isocitrate Dehydrogenase-Mutated Cholangiocarcinoma: Natural History and Clinical Outcomes.

Grant A WintheiserTyler ZemlaQian ShiNguyen H TranKritika PrasaiSri Harsha TellaKabir ModyDaniel AhnMitesh J Borad Tanios S Bekaii-Saab Amit Mahipal

Published in: JCO precision oncology (2022)

confers a unique subtype resulting in a better survival compared with that of counterparts. IDH inhibitors represent a promising therapeutic option in later lines of therapy in this subgroup.

Keyphrases

wild type
low grade
free survival
stem cells
clinical trial
cell therapy
open label